Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada

Value in Health

Volumn 15, Issue 6, 2012, Pages 894-906

  He, Jing ^a,b,c   Bowen, James M ^b,c   Xie, Feng ^b,c   Goeree, Ron ^b,c  

^a CANADIAN INSTITUTE FOR HEALTH INFORMATION   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

antiviral treatments; chronic hepatitis B; cost effectiveness analysis; Markov modeling; probabilistic sensitivity analysis

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL;

ADD ON THERAPY; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL THERAPY; ARTICLE; CANADA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HIDDEN MARKOV MODEL; HUMAN; INCIDENCE; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STATISTICS;

ADULT; ANTIVIRAL AGENTS; CANADA; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84866421359     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.06.005     Document Type: Article

References (69)

1. K.W. Burak, C.S. Coffin, R.P. Myers Hepatitis B awareness and education: a failing grade Can J Gastroenterol 25 2011 125 126
2. M. Sherman, S. Shafran, K. Burak Management of chronic hepatitis B: consensus guidelines Can J Gastroenterol 21 Suppl. C 2007 5C 24
3. Ontario Burden of Infectious Disease study (ONBOIDS), December 2010 www.oahpp.ca/resources/documents/reports/onboid/ONBOID-EXCEUTIVE-SUMMARY.pdf [Accessed July 30, 2011]
4. P. Marotta, K. Lucas Management of hepatitis B: a longitudinal national survey - impact of the Canadian Hepatitis B Consensus Guidelines Can J Gastroenterol 24 2010 537 542
5. G. Woo, G. Tomlinson, Y. Nishikawa Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses Gastroenterology 139 2010 1218 1229
6. H. Dakin, C. Fidler, C. Harper Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B Value Health 13 2010 934 945
7. Guidelines for the Economic Evaluation of Health Technologies: Canada (3rd ed) 2006 Canadian Agency for Drugs and Technologies in Health Ottawa, Canada
8. Statistics Canada Table 7b Complete life table, Ontario, 2000 to 2002 http://www.statcan.gc.ca/pub/84-537-x/4064441-eng.htm [Accessed July 2, 2011]
9. A.S. Lok, B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
10. G. Fattovich, G. Giustina, S.W. Schalm Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis Hepatology 21 1995 77 82
11. C. Niederau, T. Heintges, S. Lange Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1996 1422 1427
12. F.E. de Jongh, H.L. Janssen, R.A. de Man Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver Gastroenterology 103 1992 1630 1635
13. M.W. Yu, F.C. Hsu, I.S. Sheen Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers Am J Epidemiol 145 1997 1039 1047
14. G. Fattovich, L. Brollo, G. Giustina Natural history and prognostic factors for chronic hepatitis type B Gut 32 1991 294 298
15. Y.F. Liaw, J.J. Sung, W.C. Chow Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
16. J.G. Reijnders, M.J. Perquin, N. Zhang Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B Gastroenterology 139 2010 491 498
17. Y.M. Wang, Y.K. Chen, D.Z. Zhang [A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B] Zhonghua Gan Zang Bing Za Zhi 14 2006 803 805
18. S.W. Cho, Y.J. Cho, J.Y. Cheong [Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients] Korean J Gastroenterol 56 2010 83 89
19. G.E. Chung, W. Kim, K.L. Lee Add-on adefovir is superior to a switch to entecavir as rescue therapy for lamivudine-resistant chronic hepatitis B Dig Dis Sci 56 2011 2130 2136
20. Y.M. Gagnon, A.R. Levy, U.H. Iloeje, A.H. Briggs Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection J Clin Gastroenterol 38 Suppl. 2004 S179 S186
21. P. Marcellin, E.J. Heathcote, M. Buti Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
22. R.G. Gish, A.S. Lok, T.T. Chang Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B Gastroenterology 133 2007 1437 1444
23. J. Hou, Y.K. Yin, D. Xu Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial Hepatology 47 2008 447 454
24. C.L. Lai, E. Gane, Y.F. Liaw Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2007 2576 2588
25. D.J. Tenney, R.E. Rose, C.J. Baldick Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
26. J.L. Dienstag, J. Cianciara, S. Karayalcin Durability of serologic response after lamivudine treatment of chronic hepatitis B Hepatology 37 2003 748 755
27. R.G. Gish, T.T. Chang, R.A. De Man Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022) Hepatology 42 4, Suppl. 1 2005 267A 268
28. G.K. Lau Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion Liver Int 30 2010 512 520
29. K.M. Lee, S.W. Cho, S.W. Kim Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion J Viral Hepat 9 2002 208 212
30. T. Poynard, J. Hou, A. Chutaputti Sustained durability of HBeAG seroconversion in chronic hepatitis B patients after treatment with telbivudine J Hepatol 48 Suppl. 2008 S263 S264
31. B.C. Song, D.J. Suh, H.C. Lee Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
32. U.H. Iloeje, H.I. Yang, J. Su Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 2006 678 686
33. T.T. Chang, R.G. Gish, M.R. de A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010
34. J.R. Eun, H.J. Lee, T.N. Kim, K.S. Lee Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease J Hepatol 53 2010 118 125
35. H.I. Yang, M.F. Yuen, H.L. Chan Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score Lancet Oncol 12 2011 568 574
36. E.J. Heathcote, P. Marcellin, M. Buti Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
37. Y. Kato, K. Nakao, K. Hamasaki Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan J Gastroenterol 35 2000 201 205
38. Y.S. Hsu, R.N. Chien, C.T. Yeh Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527
39. M.J. Sonneveld, R. Zoutendijk, H.L. Janssen Hepatitis B surface antigen monitoring and management of chronic hepatitis B J Viral Hepat 18 2011 449 457
40. R.P. Perrillo Current treatment of chronic hepatitis B: benefits and limitations Semin Liver Dis 25 Suppl. 1 2005 20 28
41. T.J. Wilt, T. Shamliyan, A. Shaukat Management of chronic hepatitis B Evid Rep Technol Assess (Full Rep) 174 2008 1 671
42. S. Locarnini Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure Hepatol Int 2 2008 147 151
43. A. Snow-Lampart, B. Chappell, M. Curtis No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
44. N.B. Ha, R.T. Garcia, H.N. Trinh Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B Dig Dis Sci 56 8 2011 2423 2431
45. C.F. Wu, M.W. Yu, C.L. Lin Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men Carcinogenesis 29 2008 106 112
46. P. Michielsen, E. Ho Viral hepatitis B and hepatocellular carcinoma Acta Gastroenterol Belg 74 2011 4 8
47. K. Tziomalos Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B World J Hepatol 2 2010 91 93
48. Y.F. Liaw, I.S. Sheen, T.J. Chen Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study Hepatology 13 1991 627 631
49. J.P. Villeneuve, M. Desrochers, C. Infante-Rivard A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal Gastroenterology 106 1994 1000 1005
50. G. Fattovich, M. Pantalena, I. Zagni Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients Am J Gastroenterol 97 2002 2886 2895
51. J.P. Villeneuve, L.D. Condreay, B. Willems Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B Hepatology 31 2000 207 210
52. E.K. Teo, S.H. Han, N. Terrault Liver transplantation in patients with hepatitis B virus infection: outcome in Asian versus white patients Hepatology 34 2001 126 132
53. G. Fattovich, G. Giustina, F. Degos Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
54. S. Jung, D.J. Suh, H.J. Park [Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea] Taehan Kan Hakhoe Chi 8 2002 418 427
55. T. Kuzuya, Y. Katano, T. Kumada Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma J Gastroenterol Hepatol 22 2007 1929 1935
56. W.R. Kim, J.J. Poterucha, W.K. Kremers Outcome of liver transplantation for hepatitis B in the United States Liver Transpl 10 2004 968 974
57. E.C. Seaberg, S.H. Belle, K.C. Beringer Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry Clin Transpl 1998 17 37
58. Régie de l'assurance maladie duQuébec List of medications (July 6, 2011) https://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste-Med/ Liste-Med/liste-med-mod1-2011-07-06-en.pdf [Accessed July 8, 2011]
59. McKesson Canada http://www.mckesson.ca/en/customer-access [Accessed July 5, 2011]
60. Ontario Drug Benefit Formulary/Comparable Drug Index (Edition No. 4) 2008 Ontario Ministry of Health Ontario, Canada
61. D.E. Spackman, D.L. Veenstra A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B Pharmacoeconomics 26 2008 937 949
62. Exhange-rates.org USD (US dollars) to CAD (Canadian dollars) exchange rate for December 18, 2008 http://www.exchange-rates.org/Rate/USD/CAD/12-18-2008 [Accessed July 5, 2011]
63. Statistics Canada CANSIM:2011070513485426989, consumer price index (health care) http://www.statcan.gc.ca/datawarehouse/paiement/paiement.cgi? demande-id=2011070513485426989 [Accessed July 5, 2011]
64. Statistics Canada Table 326-0021 - consumer price index (CPI), CANSIM (database) http://www5.statcan.gc.ca/cansim/a01?lang=eng [Accessed July 5, 2011]
65. A.R. Levy, K.V. Kowdley, U. Iloeje The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons Value Health 11 2008 527 538
66. A. Briggs, K. Claxton, M. Sculpher Decision Modelling for Health Economic Evaluation 2006 Oxford University Press New York
67. Y. Yuan, U.H. Iloeje, J. Hay, S. Saab Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients J Manag Care Pharm 14 2008 21 33
68. M. Buti, M. Brosa, M.A. Casado Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B J Hepatol 51 2009 640 646
69. X. Sun, T. Faunce Decision-analytical modelling in health-care economic evaluations Eur J Health Econ 9 2008 313 323